(Q37696508)

22 August 2017

1 reference

title

Pioglitazone: side effect and safety profile (English)

1 reference

22 August 2017

Priya Shah

1

1 reference

PubMed ID

20175701

22 August 2017

Sunder Mudaliar

series ordinal

2

1 reference

PubMed ID

20175701

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Drug Safety

22 August 2017

1 reference

22 August 2017

9

1 reference

22 August 2017

2

1 reference

22 August 2017

347-354

1 reference

The pharmacokinetics of pioglitazone in patients with impaired renal function

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Weight gain in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Bone metabolism in type 2 diabetes and role of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Thiazolidinediones: antidiabetic agents with effects on bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Diabetes drug pioglitazone (Actos): risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Thiazolidinedione use and the risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003623218

10.1517/14740331003623218

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20175701